APO Research
Talk to an analyst

APO RESEARCH · REPORT

Urological Cancer Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Urological Cancer Drugs Market Outlook and Growth Opportunities 2026

20 December 2025205 pages

Choose your research edition.

Industry ResearchUrological Cancer Drugs Industry Research Report 2026136 pages · $2,950 USDIndustry Growth & TrendsGlobal Urological Cancer Drugs Industry Growth and Trends Forecast to 2032116 pages · $3,450 USDMarket StructureGlobal Urological Cancer Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Urological Cancer Drugs Market Outlook and Growth Opportunities 2026205 pages · $4,250 USDMarket Analysis & ForecastGlobal Urological Cancer Drugs Market Analysis and Forecast 2026-2032205 pages · $4,950 USD

Market perspective

The global Urological Cancer Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Urological Cancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Urological Cancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Urological Cancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Urological Cancer Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Urological Cancer Drugs market include Johnson & Johnson, Novartis, Pfizer, GlaxoSmithKline, AstraZeneca, Tolmar Inc, Sanofi S.A, Roche Healthcare and Ipsen, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Urological Cancer Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Urological Cancer Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Urological Cancer Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Urological Cancer Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Urological Cancer Drugs Segment by Company

Johnson & Johnson

Novartis

Pfizer

GlaxoSmithKline

AstraZeneca

Tolmar Inc

Sanofi S.A

Roche Healthcare

Ipsen

Indevus Pharmaceuticals Inc

Ferring Pharmaceuticals

Dendreon Corporation

Celgene Corporation

Bristol-Myers Squibb

Astellas

Abbott Laboratories

Urological Cancer Drugs Segment by Type

Tablets

Injection

Urological Cancer Drugs Segment by Application

Bladder Cancer

Testicular Cancer

Prostate Cancer

Kidney Cancer

Others

Urological Cancer Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Urological Cancer Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Urological Cancer Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Urological Cancer Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Urological Cancer Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Urological Cancer Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Urological Cancer Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Urological Cancer Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Urological Cancer Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Urological Cancer Drugs industry.

Chapter 3: Detailed analysis of Urological Cancer Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Urological Cancer Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Urological Cancer Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Urological Cancer Drugs Industry Trends Table 2. Urological Cancer Drugs Industry Drivers Table 3. Urological Cancer Drugs Industry Opportunities and Challenges Table 4. Urological Cancer Drugs Industry Restraints Table 5. Global Urological Cancer Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Urological Cancer Drugs Revenue Share by Company (2021-2026) Table 7. Global Urological Cancer Drugs Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Urological Cancer Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Urological Cancer Drugs Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Urological Cancer Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Urological Cancer Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Urological Cancer Drugs Company, Product Type & Application Table 13. Global Urological Cancer Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Urological Cancer Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Tablets Table 18. Significant Companies of Injection Table 19. Global Urological Cancer Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Urological Cancer Drugs Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Urological Cancer Drugs Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Urological Cancer Drugs Sales Volume Share by Type (2021-2026) Table 23. Global Urological Cancer Drugs Sales Volume Share by Type (2027-2032) Table 24. Global Urological Cancer Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Urological Cancer Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Urological Cancer Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Urological Cancer Drugs Sales Value Share by Type (2021-2026) Table 28. Global Urological Cancer Drugs Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Bladder Cancer Table 30. Significant Companies of Testicular Cancer Table 31. Significant Companies of Prostate Cancer Table 32. Significant Companies of Kidney Cancer Table 33. Significant Companies of Others Table 34. Global Urological Cancer Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Urological Cancer Drugs Sales Volume by Application (2021-2026) & (K Units) Table 36. Global Urological Cancer Drugs Sales Volume by Application (2027-2032) & (K Units) Table 37. Global Urological Cancer Drugs Sales Volume Share by Application (2021-2026) Table 38. Global Urological Cancer Drugs Sales Volume Share by Application (2027-2032) Table 39. Global Urological Cancer Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Urological Cancer Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Urological Cancer Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Urological Cancer Drugs Sales Value Share by Application (2021-2026) Table 43. Global Urological Cancer Drugs Sales Value Share by Application (2027-2032) Table 44. Global Urological Cancer Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Urological Cancer Drugs Sales by Region (2021-2026) & (K Units) Table 46. Global Urological Cancer Drugs Sales Market Share by Region (2021-2026) Table 47. Global Urological Cancer Drugs Sales by Region (2027-2032) & (K Units) Table 48. Global Urological Cancer Drugs Sales Market Share by Region (2027-2032) Table 49. Global Urological Cancer Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Urological Cancer Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Urological Cancer Drugs Sales Value Share by Region (2021-2026) Table 52. Global Urological Cancer Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Urological Cancer Drugs Sales Value Share by Region (2027-2032) Table 54. Global Urological Cancer Drugs Market Average Price (US$/Unit) by Region (2021-2026) Table 55. Global Urological Cancer Drugs Market Average Price (US$/Unit) by Region (2027-2032) Table 56. Global Urological Cancer Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Global Urological Cancer Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Urological Cancer Drugs Sales by Country (2021-2026) & (K Units) Table 59. Global Urological Cancer Drugs Sales Market Share by Country (2021-2026) Table 60. Global Urological Cancer Drugs Sales by Country (2027-2032) & (K Units) Table 61. Global Urological Cancer Drugs Sales Market Share by Country (2027-2032) Table 62. Global Urological Cancer Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Urological Cancer Drugs Sales Value Market Share by Country (2021-2026) Table 64. Global Urological Cancer Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Urological Cancer Drugs Sales Value Market Share by Country (2027-2032) Table 66. Johnson & Johnson Company Information Table 67. Johnson & Johnson Business Overview Table 68. Johnson & Johnson Urological Cancer Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Johnson & Johnson Urological Cancer Drugs Product Portfolio Table 70. Johnson & Johnson Recent Development Table 71. Novartis Company Information Table 72. Novartis Business Overview Table 73. Novartis Urological Cancer Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Novartis Urological Cancer Drugs Product Portfolio Table 75. Novartis Recent Development Table 76. Pfizer Company Information Table 77. Pfizer Business Overview Table 78. Pfizer Urological Cancer Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Pfizer Urological Cancer Drugs Product Portfolio Table 80. Pfizer Recent Development Table 81. GlaxoSmithKline Company Information Table 82. GlaxoSmithKline Business Overview Table 83. GlaxoSmithKline Urological Cancer Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. GlaxoSmithKline Urological Cancer Drugs Product Portfolio Table 85. GlaxoSmithKline Recent Development Table 86. AstraZeneca Company Information Table 87. AstraZeneca Business Overview Table 88. AstraZeneca Urological Cancer Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. AstraZeneca Urological Cancer Drugs Product Portfolio Table 90. AstraZeneca Recent Development Table 91. Tolmar Inc Company Information Table 92. Tolmar Inc Business Overview Table 93. Tolmar Inc Urological Cancer Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Tolmar Inc Urological Cancer Drugs Product Portfolio Table 95. Tolmar Inc Recent Development Table 96. Sanofi S.A Company Information Table 97. Sanofi S.A Business Overview Table 98. Sanofi S.A Urological Cancer Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Sanofi S.A Urological Cancer Drugs Product Portfolio Table 100. Sanofi S.A Recent Development Table 101. Roche Healthcare Company Information Table 102. Roche Healthcare Business Overview Table 103. Roche Healthcare Urological Cancer Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Roche Healthcare Urological Cancer Drugs Product Portfolio Table 105. Roche Healthcare Recent Development Table 106. Ipsen Company Information Table 107. Ipsen Business Overview Table 108. Ipsen Urological Cancer Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Ipsen Urological Cancer Drugs Product Portfolio Table 110. Ipsen Recent Development Table 111. Indevus Pharmaceuticals Inc Company Information Table 112. Indevus Pharmaceuticals Inc Business Overview Table 113. Indevus Pharmaceuticals Inc Urological Cancer Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Indevus Pharmaceuticals Inc Urological Cancer Drugs Product Portfolio Table 115. Indevus Pharmaceuticals Inc Recent Development Table 116. Ferring Pharmaceuticals Company Information Table 117. Ferring Pharmaceuticals Business Overview Table 118. Ferring Pharmaceuticals Urological Cancer Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Ferring Pharmaceuticals Urological Cancer Drugs Product Portfolio Table 120. Ferring Pharmaceuticals Recent Development Table 121. Dendreon Corporation Company Information Table 122. Dendreon Corporation Business Overview Table 123. Dendreon Corporation Urological Cancer Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Dendreon Corporation Urological Cancer Drugs Product Portfolio Table 125. Dendreon Corporation Recent Development Table 126. Celgene Corporation Company Information Table 127. Celgene Corporation Business Overview Table 128. Celgene Corporation Urological Cancer Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. Celgene Corporation Urological Cancer Drugs Product Portfolio Table 130. Celgene Corporation Recent Development Table 131. Bristol-Myers Squibb Company Information Table 132. Bristol-Myers Squibb Business Overview Table 133. Bristol-Myers Squibb Urological Cancer Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 134. Bristol-Myers Squibb Urological Cancer Drugs Product Portfolio Table 135. Bristol-Myers Squibb Recent Development Table 136. Astellas Company Information Table 137. Astellas Business Overview Table 138. Astellas Urological Cancer Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 139. Astellas Urological Cancer Drugs Product Portfolio Table 140. Astellas Recent Development Table 141. Abbott Laboratories Company Information Table 142. Abbott Laboratories Business Overview Table 143. Abbott Laboratories Urological Cancer Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 144. Abbott Laboratories Urological Cancer Drugs Product Portfolio Table 145. Abbott Laboratories Recent Development Table 146. Key Raw Materials Table 147. Raw Materials Key Suppliers Table 148. Urological Cancer Drugs Distributors List Table 149. Urological Cancer Drugs Customers List Table 150. Research Programs/Design for This Report Table 151. Authors List of This Report Table 152. Secondary Sources Table 153. Primary Sources List of Figures Figure 1. Urological Cancer Drugs Product Image Figure 2. Global Urological Cancer Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Urological Cancer Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Urological Cancer Drugs Sales (2021-2032) & (K Units) Figure 5. Global Urological Cancer Drugs Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Urological Cancer Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Tablets Image Figure 10. Injection Image Figure 11. Global Urological Cancer Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Urological Cancer Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Urological Cancer Drugs Sales Volume Share by Type (2021-2032) Figure 14. Global Urological Cancer Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Urological Cancer Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Urological Cancer Drugs Sales Value Share by Type (2021-2032) Figure 17. Bladder Cancer Image Figure 18. Testicular Cancer Image Figure 19. Prostate Cancer Image Figure 20. Kidney Cancer Image Figure 21. Others Image Figure 22. Global Urological Cancer Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Urological Cancer Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Urological Cancer Drugs Sales Volume Share by Application (2021-2032) Figure 25. Global Urological Cancer Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Urological Cancer Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Urological Cancer Drugs Sales Value Share by Application (2021-2032) Figure 28. Global Urological Cancer Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 29. Global Urological Cancer Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Urological Cancer Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Urological Cancer Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Urological Cancer Drugs Sales Value (2021-2032) & (US$ Million) Figure 33. North America Urological Cancer Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Urological Cancer Drugs Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Urological Cancer Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Urological Cancer Drugs Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Urological Cancer Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Urological Cancer Drugs Sales Value (2021-2032) & (US$ Million) Figure 39. South America Urological Cancer Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Urological Cancer Drugs Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Urological Cancer Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Urological Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Urological Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Urological Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Urological Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Urological Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Urological Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Urological Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Urological Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Urological Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Urological Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Urological Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Urological Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Urological Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Urological Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Urological Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Urological Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Urological Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Urological Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Urological Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Urological Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Urological Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Urological Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Urological Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Urological Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Urological Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Urological Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Urological Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Urological Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Urological Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Urological Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Urological Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Urological Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Urological Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Urological Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Urological Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Urological Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Urological Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Urological Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Urological Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Urological Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Urological Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Urological Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Urological Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Urological Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Urological Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Urological Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Urological Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Urological Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Urological Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Urological Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Urological Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Urological Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Urological Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Urological Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Urological Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Urological Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Urological Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Urological Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Urological Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Urological Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Urological Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Urological Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Urological Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Urological Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Urological Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Urological Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Urological Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Urological Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Urological Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Urological Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Urological Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Urological Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Urological Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Urological Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Urological Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Urological Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Urological Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Urological Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Urological Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Urological Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Urological Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Urological Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Urological Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Urological Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Urological Cancer Drugs Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Urological Cancer Drugs Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Tablets
  • Injection
Applications
  • Bladder Cancer
  • Testicular Cancer
  • Prostate Cancer
  • Kidney Cancer
  • Others
Companies covered
  • Johnson & Johnson
  • Novartis
  • Pfizer
  • GlaxoSmithKline
  • AstraZeneca
  • Tolmar Inc
  • Sanofi S.A
  • Roche Healthcare
  • Ipsen
  • Indevus Pharmaceuticals Inc
  • Ferring Pharmaceuticals
  • Dendreon Corporation
  • Celgene Corporation
  • Bristol-Myers Squibb
  • Astellas
  • Abbott Laboratories

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Urological Cancer Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Urological Cancer Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Urological Cancer Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Urological Cancer Drugs Market Dynamics
  1. 2.1 Urological Cancer Drugs Industry Trends
  2. 2.2 Urological Cancer Drugs Industry Drivers
  3. 2.3 Urological Cancer Drugs Industry Opportunities and Challenges
  4. 2.4 Urological Cancer Drugs Industry Restraints
3 Urological Cancer Drugs Market by Company
  1. 3.1 Global Urological Cancer Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Urological Cancer Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Urological Cancer Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Urological Cancer Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Urological Cancer Drugs Company Ranking (2024-2026)
  6. 3.6 Global Urological Cancer Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Urological Cancer Drugs Company Product Type and Application
  8. 3.8 Global Urological Cancer Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Urological Cancer Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Urological Cancer Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Urological Cancer Drugs Market by Type
  1. 4.1 Urological Cancer Drugs Type Introduction
  2. 4.1.1 Tablets
  3. 4.1.2 Injection
  4. 4.2 Global Urological Cancer Drugs Sales Volume by Type
  5. 4.2.1 Global Urological Cancer Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Urological Cancer Drugs Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Urological Cancer Drugs Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Urological Cancer Drugs Sales Value by Type
  9. 4.3.1 Global Urological Cancer Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Urological Cancer Drugs Sales Value by Type (2021-2032)
  11. 4.3.3 Global Urological Cancer Drugs Sales Value Share by Type (2021-2032)
5 Urological Cancer Drugs Market by Application
  1. 5.1 Urological Cancer Drugs Application Introduction
  2. 5.1.1 Bladder Cancer
  3. 5.1.2 Testicular Cancer
  4. 5.1.3 Prostate Cancer
  5. 5.1.4 Kidney Cancer
  6. 5.1.5 Others
  7. 5.2 Global Urological Cancer Drugs Sales Volume by Application
  8. 5.2.1 Global Urological Cancer Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Urological Cancer Drugs Sales Volume by Application (2021-2032)
  10. 5.2.3 Global Urological Cancer Drugs Sales Volume Share by Application (2021-2032)
  11. 5.3 Global Urological Cancer Drugs Sales Value by Application
  12. 5.3.1 Global Urological Cancer Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Urological Cancer Drugs Sales Value by Application (2021-2032)
  14. 5.3.3 Global Urological Cancer Drugs Sales Value Share by Application (2021-2032)
6 Urological Cancer Drugs Regional Sales and Value Analysis
  1. 6.1 Global Urological Cancer Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Urological Cancer Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Urological Cancer Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Urological Cancer Drugs Sales by Region (2027-2032)
  5. 6.3 Global Urological Cancer Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Urological Cancer Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Urological Cancer Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Urological Cancer Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Urological Cancer Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Urological Cancer Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Urological Cancer Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Urological Cancer Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Urological Cancer Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Urological Cancer Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Urological Cancer Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Urological Cancer Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Urological Cancer Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Urological Cancer Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Urological Cancer Drugs Sales Value Share by Country, 2025 VS 2032
7 Urological Cancer Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Urological Cancer Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Urological Cancer Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Urological Cancer Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Urological Cancer Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Urological Cancer Drugs Sales by Country (2027-2032)
  6. 7.4 Global Urological Cancer Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Urological Cancer Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Urological Cancer Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Urological Cancer Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Urological Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Urological Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Urological Cancer Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Urological Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Urological Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Urological Cancer Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Urological Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Urological Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Urological Cancer Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Urological Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Urological Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Urological Cancer Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Urological Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Urological Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Urological Cancer Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Urological Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Urological Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Urological Cancer Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Urological Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Urological Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Urological Cancer Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Urological Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Urological Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Urological Cancer Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Urological Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Urological Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Urological Cancer Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Urological Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Urological Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Urological Cancer Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Urological Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Urological Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Urological Cancer Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Urological Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Urological Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Urological Cancer Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Urological Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Urological Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Urological Cancer Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Urological Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Urological Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Urological Cancer Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Urological Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Urological Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Urological Cancer Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Urological Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Urological Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Urological Cancer Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Urological Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Urological Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Urological Cancer Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Urological Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Urological Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Urological Cancer Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Urological Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Urological Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Urological Cancer Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Urological Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Urological Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Urological Cancer Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Urological Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Urological Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Urological Cancer Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Urological Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Urological Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Urological Cancer Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Urological Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Urological Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Urological Cancer Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Urological Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Urological Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Urological Cancer Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Urological Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Urological Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Urological Cancer Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Urological Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Urological Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Urological Cancer Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Urological Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Urological Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Urological Cancer Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Urological Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Urological Cancer Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Johnson & Johnson
  2. 8.1.1 Johnson & Johnson Company Information
  3. 8.1.2 Johnson & Johnson Business Overview
  4. 8.1.3 Johnson & Johnson Urological Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Johnson & Johnson Urological Cancer Drugs Product Portfolio
  6. 8.1.5 Johnson & Johnson Recent Developments
  7. 8.2 Novartis
  8. 8.2.1 Novartis Company Information
  9. 8.2.2 Novartis Business Overview
  10. 8.2.3 Novartis Urological Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Novartis Urological Cancer Drugs Product Portfolio
  12. 8.2.5 Novartis Recent Developments
  13. 8.3 Pfizer
  14. 8.3.1 Pfizer Company Information
  15. 8.3.2 Pfizer Business Overview
  16. 8.3.3 Pfizer Urological Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Pfizer Urological Cancer Drugs Product Portfolio
  18. 8.3.5 Pfizer Recent Developments
  19. 8.4 GlaxoSmithKline
  20. 8.4.1 GlaxoSmithKline Company Information
  21. 8.4.2 GlaxoSmithKline Business Overview
  22. 8.4.3 GlaxoSmithKline Urological Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 GlaxoSmithKline Urological Cancer Drugs Product Portfolio
  24. 8.4.5 GlaxoSmithKline Recent Developments
  25. 8.5 AstraZeneca
  26. 8.5.1 AstraZeneca Company Information
  27. 8.5.2 AstraZeneca Business Overview
  28. 8.5.3 AstraZeneca Urological Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 AstraZeneca Urological Cancer Drugs Product Portfolio
  30. 8.5.5 AstraZeneca Recent Developments
  31. 8.6 Tolmar Inc
  32. 8.6.1 Tolmar Inc Company Information
  33. 8.6.2 Tolmar Inc Business Overview
  34. 8.6.3 Tolmar Inc Urological Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Tolmar Inc Urological Cancer Drugs Product Portfolio
  36. 8.6.5 Tolmar Inc Recent Developments
  37. 8.7 Sanofi S.A
  38. 8.7.1 Sanofi S.A Company Information
  39. 8.7.2 Sanofi S.A Business Overview
  40. 8.7.3 Sanofi S.A Urological Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Sanofi S.A Urological Cancer Drugs Product Portfolio
  42. 8.7.5 Sanofi S.A Recent Developments
  43. 8.8 Roche Healthcare
  44. 8.8.1 Roche Healthcare Company Information
  45. 8.8.2 Roche Healthcare Business Overview
  46. 8.8.3 Roche Healthcare Urological Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Roche Healthcare Urological Cancer Drugs Product Portfolio
  48. 8.8.5 Roche Healthcare Recent Developments
  49. 8.9 Ipsen
  50. 8.9.1 Ipsen Company Information
  51. 8.9.2 Ipsen Business Overview
  52. 8.9.3 Ipsen Urological Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Ipsen Urological Cancer Drugs Product Portfolio
  54. 8.9.5 Ipsen Recent Developments
  55. 8.10 Indevus Pharmaceuticals Inc
  56. 8.10.1 Indevus Pharmaceuticals Inc Company Information
  57. 8.10.2 Indevus Pharmaceuticals Inc Business Overview
  58. 8.10.3 Indevus Pharmaceuticals Inc Urological Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Indevus Pharmaceuticals Inc Urological Cancer Drugs Product Portfolio
  60. 8.10.5 Indevus Pharmaceuticals Inc Recent Developments
  61. 8.11 Ferring Pharmaceuticals
  62. 8.11.1 Ferring Pharmaceuticals Company Information
  63. 8.11.2 Ferring Pharmaceuticals Business Overview
  64. 8.11.3 Ferring Pharmaceuticals Urological Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Ferring Pharmaceuticals Urological Cancer Drugs Product Portfolio
  66. 8.11.5 Ferring Pharmaceuticals Recent Developments
  67. 8.12 Dendreon Corporation
  68. 8.12.1 Dendreon Corporation Company Information
  69. 8.12.2 Dendreon Corporation Business Overview
  70. 8.12.3 Dendreon Corporation Urological Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Dendreon Corporation Urological Cancer Drugs Product Portfolio
  72. 8.12.5 Dendreon Corporation Recent Developments
  73. 8.13 Celgene Corporation
  74. 8.13.1 Celgene Corporation Company Information
  75. 8.13.2 Celgene Corporation Business Overview
  76. 8.13.3 Celgene Corporation Urological Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Celgene Corporation Urological Cancer Drugs Product Portfolio
  78. 8.13.5 Celgene Corporation Recent Developments
  79. 8.14 Bristol-Myers Squibb
  80. 8.14.1 Bristol-Myers Squibb Company Information
  81. 8.14.2 Bristol-Myers Squibb Business Overview
  82. 8.14.3 Bristol-Myers Squibb Urological Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Bristol-Myers Squibb Urological Cancer Drugs Product Portfolio
  84. 8.14.5 Bristol-Myers Squibb Recent Developments
  85. 8.15 Astellas
  86. 8.15.1 Astellas Company Information
  87. 8.15.2 Astellas Business Overview
  88. 8.15.3 Astellas Urological Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Astellas Urological Cancer Drugs Product Portfolio
  90. 8.15.5 Astellas Recent Developments
  91. 8.16 Abbott Laboratories
  92. 8.16.1 Abbott Laboratories Company Information
  93. 8.16.2 Abbott Laboratories Business Overview
  94. 8.16.3 Abbott Laboratories Urological Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Abbott Laboratories Urological Cancer Drugs Product Portfolio
  96. 8.16.5 Abbott Laboratories Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Urological Cancer Drugs Value Chain Analysis
  2. 9.1.1 Urological Cancer Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Urological Cancer Drugs Sales Mode & Process
  6. 9.2 Urological Cancer Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Urological Cancer Drugs Distributors
  9. 9.2.3 Urological Cancer Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst